Text Size: a  |   a 

Amiselimod May Decrease Lesions in Relapsing MS

September 15, 2016

Two different types of doses of amiselimod showed to reduce lesions in patients suffering from relapsing- remitting MS (RRMS).

The phase 2 momentum trial included 415 adult patients with RRMS. It showed that those who received oral amiselimod, 0.2 mg or 0.4 mg once daily, had significantly greater reductions in T1-weighted lesions on MRI after 24 weeks of treatment than those who received matching placebo.

Both doses of the treatment, formerly known as MT-1303, also showed significant reductions in new or enlarged T2-weighted lesions, with 55% and 69% reduction rates, respectively. Plus, 85% and 86% of the treatment group members were relapse-free at week 24.

Perhaps most importantly, the amiselimod groups did not report any “clinically significant” cardiac events.

"The safety and efficacy profiles of amiselimod suggest that this…is a new potential treatment in multiple sclerosis and potentially other immune-mediated inflammatory diseases and deserves further investigation," write the investigators, led by Ludwig Kappos, professor of neurology at University Hospital Basel, Switzerland.

The findings were published online August 16 in Lancet Neurology.